Androcur the patient will now have to sign a form informing him of the risks of developing a tumor - Europe 1
Androcur, this drug indicated in particular against hyperpilosity, can multiply up to twenty the risk of developing a non -cancerous brain tumor. From July 1, any patient starting treatment must be informed of the risk and sign an annual information certificate.
As of July 1, any patient starting treatment with Androcur or his generics must be informed of the risk of a tumor linked to these drugs and benefit from a brain imaging examination, according to the drug agency. "This information mainly concerns women, cyproterone acetate, an active ingredient for these drugs, being a minority prescribed to men, especially for prostate cancer and sexual deviating (chemical castration for pedophilia and/or repeated rapes)", explains Dr. Jean-Michel Race, endocrinologist, ANSM.
An information sheet on the risk of meningioma (most often benign tumor) of these drugs must now be given by prescribing doctors to their patients. The latter will only be able to obtain these drugs in pharmacy on the compulsory presentation of an annual information certificate that they have signed as well as the prescribing doctor, from July 1 for new treatments and January 1, 2020 for renewals.
Find the other Amavea articles here
